CME Activities

Topical Management of Plaque Psoriasis—A Review and Case Series Discussion with Focus on Aryl Hydrocarbon Receptor Modulation

J Clin Aesthet Dermatol. 2023;16(9 Suppl 1):S3-S12

by Matthew Bruno, PA-C, Bruce Strober, MD, PhD, and James Q. Del Rosso, DO

Jointly sponsored byMatrix Medical Communications, West Chester, Pennsylvania; Ciné-Med, Woodbury, Connecticut

Supported by—Dermavant Sciences Inc., Long Beach, California

HOW TO CLAIM CME

  1. Read the entire supplement: Click here to read
  2. Learners can claim CME credit by completing a series of assessment questions using the following URL: https://cine-med.com/certificate.php?redirect=tmpp2023.
  3. Participants will be able to download or print a certificate once the form has been submitted.

ABOUT THIS CME ACTIVITY

Release/expiration. Release Date: 9/1/23; Expiration Date: 9/1/24

Target audience. This activity is designed for dermatologists, nurse practitioners and physician assistants that treat patients with psoriasis and chronic skin conditions.  Content will be applicable to physicians of all levels, novice to advanced learner.

Learning objectives. At the completion of this activity, participants should be able to:

  • Review and differentiate topical treatment options for plaque psoriasis.
  • Discuss the role of AHR in skin health and chronic skin conditions such as psoriasis.
  • Define the role of AHR modulation in the treatment of psoriasis.
  • Describe the indications, mechanisms of action, and potential adverse effects of an FDA-approved topical AHR modulating agent in the treatment of psoriasis.
  • Identify patients with psoriasis for whom treatment with a topical AHR modulating agent may be beneficial.
  • Effectively communicate to patients the potential risks and benefits associated with topical AHR modulating therapy.


Activity goal
. This activity is designed to address the following core and team competencies: Medical Knowledge, Practice-based Learning, Patient-centered Care, and Teams and Teamwork.

Nonendorsement statement. The provider verifies that sound education principles have been demonstrated in the development of this educational offering as evidenced by the review of its objectives, teaching plan, faculty, and activity evaluation process.  The provider does not endorse or support the actual opinions or material content as presented by the speaker(s) and/or sponsoring organization.

Disclosure. The provider adheres to accreditation requirements regarding industry support of continuing medical education. Disclosure of the planning committee and faculty’s commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations. – All provider employees, activity planners, and program chairs in control of content have indicated that they have no relevant financial relationships to disclose.

Disclosed Relationships. Matthew Bruno, PA-C: Bristol-Myer Squib, AbbVie, Sanofi-Regeneron, Dermavant, Novan, Ortho Dermatologic, Mayne Pharma, UCB, Pfizer, Verrica– Consultant, Advisor, James Del Rosso, DO: Dermavant – Consultant, Speaker, Researcher; Bruce Strober, MD, PhD: AbbVie, Arcutis, Dermavant, Janssen, Eli Lilly – Consultant, Speaker; Alamar, Almirall, Amgen, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Kangpu Pharmaceuticals, Bristol-Myers-Squibb, Connect Biopharma, Evelo Biosciences, Leo – Consultant; CorEvitas – Consultant, Scientific Co-Director, Investigator.

Accreditation. In support of improving patient care, this activity has been planned and implemented by Cine-Med and Matrix Medical Communications. Cine-Med is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Cine-Med designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and other allied healthcare professionals. All other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for activities designated for AMA PRA Category 1 Credits™, consult your professional licensing board.

Commercial support. This activity is being supported by an educational grant from Dermavant Sciences, Inc.